Assembly Biosciences (ASMB) Competitors $29.45 +0.37 (+1.27%) Closing price 04:00 PM EasternExtended Trading$29.64 +0.19 (+0.63%) As of 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ASMB vs. OMER, CPIX, LLY, JNJ, ABBV, MRK, PFE, BMY, ZTS, and RPRXShould you be buying Assembly Biosciences stock or one of its competitors? The main competitors of Assembly Biosciences include Omeros (OMER), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol Myers Squibb (BMY), Zoetis (ZTS), and Royalty Pharma (RPRX). These companies are all part of the "pharmaceuticals" industry. Assembly Biosciences vs. Its Competitors Omeros Cumberland Pharmaceuticals Eli Lilly and Company Johnson & Johnson AbbVie Merck & Co., Inc. Pfizer Bristol Myers Squibb Zoetis Royalty Pharma Assembly Biosciences (NASDAQ:ASMB) and Omeros (NASDAQ:OMER) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation. Is ASMB or OMER more profitable? Omeros has a net margin of 0.00% compared to Assembly Biosciences' net margin of -117.20%. Omeros' return on equity of 0.00% beat Assembly Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Assembly Biosciences-117.20% -149.01% -39.04% Omeros N/A N/A -55.49% Do insiders & institutionals have more ownership in ASMB or OMER? 19.9% of Assembly Biosciences shares are owned by institutional investors. Comparatively, 48.8% of Omeros shares are owned by institutional investors. 5.3% of Assembly Biosciences shares are owned by company insiders. Comparatively, 12.9% of Omeros shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media favor ASMB or OMER? In the previous week, Omeros had 23 more articles in the media than Assembly Biosciences. MarketBeat recorded 33 mentions for Omeros and 10 mentions for Assembly Biosciences. Omeros' average media sentiment score of 0.53 beat Assembly Biosciences' score of 0.21 indicating that Omeros is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Assembly Biosciences 0 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Omeros 8 Very Positive mention(s) 8 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, ASMB or OMER? Assembly Biosciences has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, Omeros has a beta of 2.32, meaning that its share price is 132% more volatile than the S&P 500. Which has higher valuation and earnings, ASMB or OMER? Assembly Biosciences has higher revenue and earnings than Omeros. Assembly Biosciences is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAssembly Biosciences$28.52M7.92-$40.18M-$5.58-5.28OmerosN/AN/A-$156.82M-$2.11-3.84 Do analysts prefer ASMB or OMER? Assembly Biosciences presently has a consensus target price of $41.25, indicating a potential upside of 40.07%. Omeros has a consensus target price of $27.50, indicating a potential upside of 239.51%. Given Omeros' stronger consensus rating and higher possible upside, analysts plainly believe Omeros is more favorable than Assembly Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Assembly Biosciences 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57Omeros 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 2.75 SummaryOmeros beats Assembly Biosciences on 12 of the 16 factors compared between the two stocks. Get Assembly Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ASMB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ASMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ASMB vs. The Competition Export to ExcelMetricAssembly BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$223.11M$4.47B$6.11B$10.51BDividend YieldN/A0.89%5.73%4.81%P/E Ratio-5.2810.8584.5227.09Price / Sales7.9221.85609.45131.82Price / CashN/A7.0637.1661.22Price / Book5.614.2712.246.52Net Income-$40.18M-$134.23M$3.32B$276.75M7 Day Performance11.09%1.74%0.76%0.92%1 Month Performance42.82%18.13%8.03%4.20%1 Year Performance62.71%66.79%71.13%37.86% Assembly Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ASMBAssembly Biosciences3.5093 of 5 stars$29.45+1.3%$41.25+40.1%+65.3%$223.11M$28.52M-5.28100Analyst ForecastOMEROmeros4.3192 of 5 stars$4.61+0.7%$18.00+290.5%+137.4%$311.70MN/A-2.18210Trending NewsAnalyst ForecastAnalyst RevisionGap DownCPIXCumberland Pharmaceuticals0.6329 of 5 stars$3.09-1.3%N/A+173.8%$46.83M$37.87M-14.0580LLYEli Lilly and Company4.9817 of 5 stars$845.40+0.7%$938.94+11.1%-10.7%$794.90B$45.04B55.2547,000Trending NewsAnalyst UpgradeGap DownJNJJohnson & Johnson4.844 of 5 stars$188.23-0.2%$189.12+0.5%+16.7%$454.31B$88.82B20.13138,100Trending NewsEarnings ReportDividend AnnouncementAnalyst ForecastAnalyst RevisionABBVAbbVie4.6885 of 5 stars$230.28-1.6%$229.14-0.5%+19.1%$413.22B$56.33B109.6655,000Trending NewsAnalyst DowngradeOptions VolumeAnalyst RevisionMRKMerck & Co., Inc.5 of 5 stars$88.83-0.4%$104.31+17.4%-24.2%$222.78B$63.62B13.6975,000Trending NewsAnalyst RevisionPFEPfizer4.9564 of 5 stars$26.45-3.4%$28.41+7.4%-18.3%$155.61B$63.63B14.0781,000Trending NewsBMYBristol Myers Squibb4.974 of 5 stars$45.16-0.6%$57.14+26.5%-18.7%$92.51B$48.30B18.2134,100Trending NewsAnalyst ForecastAnalyst RevisionZTSZoetis4.8798 of 5 stars$145.39-0.7%$200.88+38.2%-26.4%$64.89B$9.26B25.0213,800Analyst RevisionRPRXRoyalty Pharma4.9874 of 5 stars$36.13+0.2%$46.00+27.3%+28.8%$21.04B$2.31B20.8880Positive NewsDividend AnnouncementShort Interest ↓ Related Companies and Tools Related Companies Omeros Alternatives Cumberland Pharmaceuticals Alternatives Eli Lilly and Company Alternatives Johnson & Johnson Alternatives AbbVie Alternatives Merck & Co., Inc. Alternatives Pfizer Alternatives Bristol Myers Squibb Alternatives Zoetis Alternatives Royalty Pharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ASMB) was last updated on 10/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Assembly Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Assembly Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
